The tiny San Mateo company risks NASDAQ stock delisting and may need to undertake a reverse stock split to buoy the stock’s price. Yet Nile also is striking into new territory — attempting to create a new indication for its early-stage drug — and forging an important deal with the world’s largest medical technology company, Medtronic Inc., that could shorten its journey.
No comments:
Post a Comment